Top NYC, NY Telehealth Companies With Best Stability & Growth (46)

Strong Market Position & Advantage: Coverage consistently characterizes Zocdoc as a U.S. category leader for consumer discovery of in‑network clinicians with instant booking across 200+ specialties. The brand is widely recognized and operates at national scale connecting millions of patients to real‑time, in‑network care.

Strategic Partnerships: Recent collaborations with health plans and health systems—such as Blue Shield of California integration and CommonSpirit pilots—demonstrate institutional traction and extended distribution beyond solo practices. These partnerships signal durable adoption and broadened channels for patient scheduling.

Profitability: Leadership states the company returned to profitability by 2023 and delivered profitable growth through 2024–2025. Earlier turnarounds to EBITDA profitability pre‑pandemic reinforce financial durability.

Investor Backing & Capital Strength: Funding announcements describe a recent nine-figure Series D at a unicorn valuation led by top-tier and strategic investors, providing substantial runway. This level of backing signals confidence in the company’s ability to scale its analytics-driven model.

Strong Revenue Growth: Coverage around the raise cites triple-digit year-over-year revenue growth alongside 700+ clients and more than 2.5 million people served, indicating accelerating commercial traction. The pace of new employer and plan adoption suggests a strengthening demand signal for its physician-quality engine.

Strong Market Position & Advantage: Materials position the company as a fast-rising leader within physician-quality analytics, leveraging a dataset spanning hundreds of millions of patient records and tying rankings to member incentives. Its analytics are also being used to power provider directories and network strategy for partners, expanding its influence in its specific lane.

Investor Backing & Capital Strength: Recent financing, including a sizable Series B in 2025, indicates strong investor confidence and runway to scale go‑to‑market and product. Reports note the raise followed observed traction rather than active fundraising, reinforcing capital strength.

Innovation-Driven Growth: A steady cadence of AI‑native releases—such as claims analytics and a platform redesign—shows momentum in automation and decision support for employees and HR. The platform’s AI assistant focus aligns with efforts to deflect HR tickets and clarify coverage.

Strategic Partnerships: Expanding routes to market via alliances and channels (e.g., PEOs/brokers and program integrations) broaden access without relying solely on direct sales. These relationships suggest increasing reach among mid‑market employers and ecosystem buyers.

Strong Revenue Growth: The company experienced a notable reacceleration in 2024 largely driven by its GLP‑1‑centered Ro Body program. Additional product launches and access to new GLP‑1 formats further supported momentum into 2025–2026.

Strategic Partnerships: Ro secured first‑tier manufacturer relationships around GLP‑1 therapies, including integrations for Zepbound and Wegovy and participation in the Wegovy pill launch. These partnerships expand access and channel credibility in obesity care.

Strong Market Position & Advantage: Ro operates a vertically integrated platform spanning telehealth, labs/diagnostics, and owned pharmacy fulfillment, reinforced by acquisitions like Workpath, Kit, and Modern Fertility. This end‑to‑end stack and nationwide reach underpin leadership claims within its DTC niche.

Strong Revenue Growth: Repeated Inc. 5000 recognition over multiple consecutive years signals sustained multi‑year top‑line expansion. Company announcements highlight ongoing product launches and acquisitions consistent with continued scaling.

Diversified Customer Base: The company serves employers, K‑12 districts, ABA practices, payors, and users across many countries, indicating breadth across end markets. Presence with large enterprises and major school systems suggests reduced dependency on any single buyer segment.

Innovation-Driven Growth: The platform leverages a uniquely large autism outcomes dataset and AI to power predictive analytics and clinical decision support. Industry awards for healthcare analytics and AI-focused executive appointments underscore innovation as a core growth driver.

Investor Backing & Capital Strength: Recent financing includes a $15.5M Series A led by Costanoa with participation from Town Hall Ventures and Khosla, bringing total funding to about $20.5M and providing resources to scale operations and technology. Coverage frames the raise as fuel for national expansion, signaling strong investor confidence.

Market Expansion: Public materials describe growth from a New York launch to hundreds of schools with 15,000+ therapy sessions and new state entries (e.g., Ohio and New Jersey), alongside active hiring across roles. Messaging emphasizes rapid access and a nationwide rollout with additional payer integrations, indicating ongoing expansion momentum.

Innovation-Driven Growth: Product investment includes an AI scribe and a proprietary therapist EHR to reduce administrative burden and increase clinician throughput. The school‑integrated workflow and group therapy programs are positioned to scale access efficiently.

Market Expansion: Multi-state therapist directories, state-specific Medicare pages, and newly formed professional entities (e.g., New York and Florida) indicate a growing geographic footprint. These signals point to operations expanding beyond a single-state pilot.

Strategic Partnerships: A collaboration with Advanced Nursing & Home Care in Maryland and Medicare in-network positioning suggest developing referral and payer channels. These relationships reinforce access to the older-adult segment Sailor targets.

Innovation-Driven Growth: An AI-native operating system for care coordination, real-time clinical insights, and billing is emphasized as a core enabler. This technology focus is positioned to free clinician time and support scalable service delivery.

Investor Backing & Capital Strength: Recent large financing and a reported unicorn valuation position the company among the best-capitalized players in insurer-covered telenutrition. Multiple outlets and investors are cited as supporting expansion of its platform, clinical network, and payer relationships.

Strong Market Position & Advantage: The company is characterized as a leader in insurance-covered, RD-led tele-nutrition with nationwide reach and broad in-network coverage. Sources highlight a very large RD workforce and payer alignment that lowers patient friction to access care.

Strategic Partnerships: Partnerships with major health plans, health systems, and adjacent services (e.g., pharma access points and medically tailored meals) extend distribution and program depth. These relationships reinforce enterprise credibility and enable growth across chronic-condition use cases.

Market Expansion: Feedback suggests Spring Health is expanding beyond employers into health plans, and the Alma acquisition is positioned to deepen payer connectivity and access. Reported coverage growth to tens of millions of eligible lives underscores widening distribution.

Investor Backing & Capital Strength: A recent $100M Series E at a multi‑billion valuation indicates strong late‑stage investor support and balance‑sheet strength. This capital base supports continued scaling, product investment, and strategic M&A.

Strong Market Position & Advantage: The company is widely viewed as part of the top tier in enterprise behavioral health, often mentioned alongside leading peers. Peer‑reviewed outcomes and third‑party cost validation bolster credibility with employers and payers.